MENU
+Compare
OVID
Stock ticker: NASDAQ
AS OF
Jun 6 closing price
Price
$0.32
Change
+$0.01 (+3.23%)
Capitalization
22.12M

OVID Ovid Therapeutics Forecast, Technical & Fundamental Analysis

Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders... Show more

OVID
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for OVID with price predictions
May 28, 2025

OVID's Stochastic Oscillator remains in oversold zone for 4 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on May 28, 2025. You may want to consider a long position or call options on OVID as a result. In of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where OVID advanced for three days, in of 267 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where OVID declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.373) is normal, around the industry mean (16.080). P/E Ratio (0.000) is within average values for comparable stocks, (59.383). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.197). Dividend Yield (0.000) settles around the average of (0.039) among similar stocks. P/S Ratio (40.323) is also within normal values, averaging (268.270).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. OVID’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OVID’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
OVID
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

OVID is expected to report earnings to rise 6.36% to -14 cents per share on August 18

Ovid Therapeutics OVID Stock Earnings Reports
Q2'25
Est.
$-0.15
Q1'25
Est.
$-0.14
Q4'24
Beat
by $0.04
Q3'24
Beat
by $0.01
Q2'24
Beat
by $0.34
The last earnings report on May 13 showed earnings per share of -14 cents, meeting the estimate of -14 cents. With 876.30K shares outstanding, the current market capitalization sits at 22.12M.
A.I. Advisor
published General Information

General Information

Provides medicines to children and adults with neurological disorders

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
441 Ninth Avenue
Phone
+1 646 661-7661
Employees
40
Web
https://www.ovidrx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL200.420.21
+0.10%
Apple
SPY587.73-3.42
-0.58%
SPDR® S&P 500® ETF
BTC.X107802.330000-1192.312500
-1.09%
Bitcoin cryptocurrency
TSLA356.90-5.99
-1.65%
Tesla
GME31.21-3.80
-10.85%
GameStop Corp

OVID and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, OVID has been closely correlated with JBIO. These tickers have moved in lockstep 79% of the time. This A.I.-generated data suggests there is a high statistical probability that if OVID jumps, then JBIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OVID
1D Price
Change %
OVID100%
-0.21%
JBIO - OVID
79%
Closely correlated
-1.63%
SYRE - OVID
45%
Loosely correlated
+0.60%
KPRX - OVID
39%
Loosely correlated
+1.35%
NRIX - OVID
37%
Loosely correlated
+2.76%
NAUT - OVID
37%
Loosely correlated
-3.95%
More

Groups containing OVID

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OVID
1D Price
Change %
OVID100%
-0.21%
OVID
(2 stocks)
11%
Poorly correlated
-0.92%